Although the engineered CD8+ T cells are highly potent in killing tumour cells, the requirement of pre-treatment with high-dose immune stimulating cytokines may alter the endogenous sensitivity to PD-1/L1-mediated immune suppression. This evidence concerns the gene CD8A and neoplasm.